288 related articles for article (PubMed ID: 22241961)
21. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
Kajiyama H; Shibata K; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Cancer; 2008 Jan; 122(1):91-9. PubMed ID: 17893878
[TBL] [Abstract][Full Text] [Related]
22. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
23. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis.
Hall JM; Korach KS
Mol Carcinog; 2013 Sep; 52(9):715-25. PubMed ID: 22549810
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the CXCL12/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis.
Shu HK; Yoon Y; Hong S; Xu K; Gao H; Hao C; Torres-Gonzalez E; Nayra C; Rojas M; Shim H
PLoS One; 2013; 8(11):e79768. PubMed ID: 24244561
[TBL] [Abstract][Full Text] [Related]
25. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.
Scotton CJ; Wilson JL; Scott K; Stamp G; Wilbanks GD; Fricker S; Bridger G; Balkwill FR
Cancer Res; 2002 Oct; 62(20):5930-8. PubMed ID: 12384559
[TBL] [Abstract][Full Text] [Related]
26. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system.
Chiaramonte R; Colombo M; Bulfamante G; Falleni M; Tosi D; Garavelli S; De Simone D; Vigolo E; Todoerti K; Neri A; Platonova N
Int J Biochem Cell Biol; 2015 Sep; 66():134-40. PubMed ID: 26235278
[TBL] [Abstract][Full Text] [Related]
27. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.
Righi E; Kashiwagi S; Yuan J; Santosuosso M; Leblanc P; Ingraham R; Forbes B; Edelblute B; Collette B; Xing D; Kowalski M; Mingari MC; Vianello F; Birrer M; Orsulic S; Dranoff G; Poznansky MC
Cancer Res; 2011 Aug; 71(16):5522-5534. PubMed ID: 21742774
[TBL] [Abstract][Full Text] [Related]
28. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
29. Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma.
Li J; Li T; Li S; Xie L; Yang YL; Lin Q; Kadoch O; Li H; Hou S; Xu Z
J Investig Med; 2019 Feb; 67(2):338-345. PubMed ID: 30367010
[TBL] [Abstract][Full Text] [Related]
30. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
Guo Q; Wu XH; Lü YP; Yang B; Xu F; Zhang SJ
Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(21):1677-80. PubMed ID: 24125682
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity.
Gatti M; Pattarozzi A; Bajetto A; Würth R; Daga A; Fiaschi P; Zona G; Florio T; Barbieri F
Toxicology; 2013 Dec; 314(2-3):209-20. PubMed ID: 24157575
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.
Xue LJ; Mao XB; Ren LL; Chu XY
Cancer Med; 2017 Jun; 6(6):1424-1436. PubMed ID: 28544785
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
34. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH
J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
[TBL] [Abstract][Full Text] [Related]
37. The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells.
Yoshida D; Koketshu K; Nomura R; Teramoto A
J Neurooncol; 2010 Oct; 100(1):51-64. PubMed ID: 20309720
[TBL] [Abstract][Full Text] [Related]
38. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
39. CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3.
Feng W; Huang W; Chen J; Qiao C; Liu D; Ji X; Xie M; Zhang T; Wang Y; Sun M; Tian D; Fan D; Nie Y; Wu K; Xia L
Theranostics; 2021; 11(6):2612-2633. PubMed ID: 33456563
[No Abstract] [Full Text] [Related]
40. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
